Hall of Fame

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors playing a critical role in the regulation of metabolic homeostasis, and thus represent valuable therapeutic targets for the treatment of metabolic disorders. The PPAR family comprises three different subtypes: α, β/δ, and γ, whose expression and actions differ according to subtype, organ, and tissue cell type. The development of more balanced drugs interacting with PPARs, devoid of the side-effects showed by some marketed agonists, is considered a major challenge. We recently reported a novel PPAR pan-agonist, AL29-26, with an attractive and balanced activity profile, which represents an interesting lead of a new...